FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.

Start Date13 Jul 2022

Sponsor / Collaborator

POINT Biopharma, Inc.

100 Clinical Results associated with 68Ga-PNT6555

100 Translational Medicine associated with 68Ga-PNT6555

100 Patents (Medical) associated with 68Ga-PNT6555

Literatures (Medical) associated with 68Ga-PNT6555

01 Jan 2024·Journal of Nuclear Medicine

Preclinical Development of PNT6555, a Boronic Acid–Based, Fibroblast Activation Protein-α (FAP)–Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors

Article

Author: Wu, Wengen ; Belanger, Anthony P ; Jones, Barry ; Pan, Shuang ; Bachovchin, William W ; Hergott, Valerie S ; Poplawski, Sarah E ; Nguyen, Quang-De ; Ahn, Shin Hye ; Novakowski, Kyle E ; Lai, Jack H ; Hallett, Robin M ; McCann, Joe A B ; Dornan, Mark H ; Liu, Yuxin ; Felten, Albert E

The overexpression of fibroblast activation protein-α (FAP) in solid cancers relative to levels in normal tissues has led to its recognition as a target for delivering agents directly to tumors. Radiolabeled quinoline-based FAP ligands have established clinical feasibility for tumor imaging, but their therapeutic potential is limited due to suboptimal tumor retention, which has prompted the search for alternative pharmacophores. One such pharmacophore is the boronic acid derivative N-(pyridine-4-carbonyl)-d-Ala-boroPro, a potent and selective FAP inhibitor (FAPI). In this study, the diagnostic and therapeutic (theranostic) potential of N-(pyridine-4-carbonyl)-d-Ala-boroPro-based metal-chelating DOTA-FAPIs was evaluated. Methods: Three DOTA-FAPIs, PNT6555, PNT6952, and PNT6522, were synthesized and characterized with respect to potency and selectivity toward soluble and cell membrane FAP; cellular uptake of the Lu-chelated analogs; biodistribution and pharmacokinetics in mice xenografted with human embryonic kidney cell-derived tumors expressing mouse FAP; the diagnostic potential of ⁶⁸Ga-chelated DOTA-FAPIs by direct organ assay and small-animal PET; the antitumor activity of ¹⁷⁷Lu-, ²²⁵Ac-, or ¹⁶¹Tb-chelated analogs using human embryonic kidney cell-derived tumors expressing mouse FAP; and the tumor-selective delivery of ¹⁷⁷Lu-chelated DOTA-FAPIs via direct organ assay and SPECT. Results: DOTA-FAPIs and their ^natGa and ^natLu chelates exhibited potent inhibition of human and mouse sources of FAP and greatly reduced activity toward closely related prolyl endopeptidase and dipeptidyl peptidase 4. ⁶⁸Ga-PNT6555 and ⁶⁸Ga-PNT6952 showed rapid renal clearance and continuous accumulation in tumors, resulting in tumor-selective exposure at 60 min after administration. ¹⁷⁷Lu-PNT6555 was distinguished from ¹⁷⁷Lu-PNT6952 and ¹⁷⁷Lu-PNT6522 by significantly higher tumor accumulation over 168 h. In therapeutic studies, all 3 ¹⁷⁷Lu-DOTA-FAPIs exhibited significant antitumor activity at well-tolerated doses, with ¹⁷⁷Lu-PNT6555 producing the greatest tumor growth delay and animal survival. ²²⁵Ac-PNT6555 and ¹⁶¹Tb-PNT6555 were similarly efficacious, producing 80% and 100% survival at optimal doses, respectively. Conclusion: PNT6555 has potential for clinical translation as a theranostic agent in FAP-positive cancer.

100 Deals associated with 68Ga-PNT6555

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	CA	POINT Biopharma Corp.	17 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

68Ga-PNT6555

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation